Phillip Pearl
Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1902983257
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,327 of the $49,504 with a category attached, or 79.4%. 10 manufacturers reported payments, led by PTC Therapeutics, Inc. at 53.8% of the total. 2025 is the largest year on record at $19,400, 9.4 times the $2,061 reported in 2019. Among neurology with special qualifications in child neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1414.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$27K
- Immedica Pharma US, Inc.$15K
- Neurelis, Inc.$3K
- Biocodex, Inc.$2K
- DIXI Medical USA Corp$833
- Biogen$810
- plus $1K from 4 others
Across 13 payments — averaging $15,828 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$197K
- Medicure Pharma Inc.$8K
What the payments were for
- Consulting fees$39,32779%
- Speaking & faculty fees$2,3955%
- Travel & lodging$6,15212%
- Food & beverage$1,6113%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 15 | $26,608 |
| Immedica Pharma US, Inc. | 2 | $15,000 |
| Neurelis, Inc. | 4 | $2,985 |
| Biocodex, Inc. | 3 | $2,049 |
| DIXI Medical USA Corp | 1 | $833 |
| Biogen | 1 | $810 |
| Medicure Pharma Inc. | 1 | $500 |
| Aquestive Therapeutics, Inc. | 1 | $255 |
| SK Life Science, Inc. | 3 | $244 |
| UCB, Inc. | 4 | $219 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PEGZILARGINASE$7,500
- KEBILIDI$4,400
- VALTOCO$2,981
- DIACOMIT$2,009
- XCOPRI$231
How this compares
$49,504 in reported general payments places this provider in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KeppraLevetiracetam | 22 | $14,584 |
| Clobazam | 12 | $3,597 |
| Lamotrigine | 37 | $716 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Boston
- Elizabeth ThieleBoston$278K
- Jurriaan PetersBoston$265K
- Basil DarrasBoston$253K
- Kiran MaskiBoston$105K
- Alexander RotenbergBoston$34K
- Irina AnselmBoston$30K
- Nicole UllrichBoston$26K
- David LiebermanBoston$19K
- Robert StoweBoston$9K
- Siddharth SrivastavaBoston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.